You are here:

FTSE 350 Outlook: Reckitt Benckiser

Created:
24 January 2008
Written by:
Amanda Vermeulen

The world's largest household goods maker ended 2007 on a high point - buying Adams Respiratory Therapeutics , a US pharmaceuticals group, for £1.1bn will help Reckitt Benckiser scale up its global over-the-counter drugs business.

Advertising

The group is highly-regarded by analysts, and it's easy to see why. At its third-quarter results at the end of October, the group raised its full-year net revenue growth target to 9 per cent at constant exchange rates and upgraded its earnings guidance to 15 per cent growth. Drivers include new products such as Air Wick Freshmatic and Vanish Crystal White, and strong sales from health and personal care products including Dettol, Nurofen and Strepsils. True, the shares trade on a far from bargain basement 22 times 2007 earnings. But as one of the highest quality companies in the consumer staples universe, that looks fully warranted and the shares continue to rate medium-term good value at 2,700p.

Company name Price (p) Mkt val. (£m) P/E ratio Div. yld (%) 12M price chng.(%) Last IC view
RECKITT BENCKISER 2584 18,398 21.1 1.93 5.25 Good value, 2769p, 25 Jul 2007


MORE FTSE 350 OUTLOOK SECTORS

GoodValue

See also:

Pharmaceuticals & healthcare

Pubs

Food producers

Gaming operators

Transport

Real estate

For a full table of contents for the FTSE 350 Outlook series, click here.


  • Back to top

Products and Services from Barclays Stockbrokers.

The UK’s No.1 Stockbroker

Stocks and Shares

Contracts for Difference

Financial Spread Trading

Gilts and Bonds

Funds Market

FX

Education Centre

Trading Simulator

Advertorial Feature

Spread your risks with spread trading

With so many big moves in the world's financial markets, there have seldom been more opportunities around for spread traders. Isn't it time you joined them?

by Dominic Picarda